An Ode to FAR....., page-92

First 92 Last

Share
Profile

Follow
zacma

2,314 Posts.

593

20/01/16

13:31

Post #: 16832462
Share

Originally posted by dangar ↑

OFL wrote -

The next step ,if we do a CR at .07c for $130m AUD then we end up with an additional 1.9b shares which takes us to 5.6b shares therefore being diluted by 34%

OFL, remember can only issue another 15% of total on issue per year without SH approval.

But as others have said, we cannot run this to production without considerable capital costs which will mean either debt or more dilution. Which means it is very hard IMO to see the value of what is one share today (which may well become a 10th or 20th of a future share on the ASX after a consolidation) reach the magic $1.

My opinion is that debt is cheaper than dilution when you have a solid business plan for making loads of income, but if you have a significant element of risk dilution is the safer option.

Wouldn't mind seeing an option issue for capital raising at this stage. That allows investors with an appetite for risk to be well rewarded and reduces dilution for current holders. For example, 1B options with a strike price of 15c and 2 year expiry date with an issue price of 2c would raise $20M now, and another $150M if they hit the money. Investors would break even at 17c, make two bags at 19c (a bit less than what buyers on market today would make), five bags at 25c (compared about 3.5 buying at current price) and 10 bags at 35c (compared to only 5 buying at 7c).
Holders happy with what they have suffer no dilution until the SP doubles, then they have a 22% dilution instead of your 34% raising $170M in total instead of your $130M.

Understand that doesn't help much if you need money now, but it's a thought. Maybe attaching options to a rights issue would work.

Expand

Our SP gets hammered whatever we do.
I hate to say this, but it will take one of three things here:
1) The POO rises, preferably with Tony's J curve.
2) Declare commercial.
3) Get an offer, low ball or otherwise.
Until such time we are at the mercy of the shorters, accumulators or who else.
Its sad, but so be it.
I know it will be OK, these characters shall not win. The pendulum will swing

FAR Price at posting: 7.0¢ Sentiment: Hold Disclosure: Held
22 Upvote

0 Great analysis

Reply

Top Stories

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

PL3

Patagonia looks to raise $2.15M for South American exploration and development

There are more pages in this discussion • 5 more messages in this thread...

First 92 Last

Add FAR (ASX) to my watchlist

(20min delay)
Last 52.0¢		Change 0.000(0.00%)		Mkt cap ! $48.05M

Open	High	Low	Value	Volume
52.0¢	52.0¢	52.0¢	$1.562K	3.004K

Buyers (Bids)

No.	Vol.	Price($)
1	17440	51.5¢

Sellers (Offers)

Price($)	Vol.	No.
54.0¢	22471	1

View Market Depth

No.	Vol.	Price($)
1	17440	0.515
2	35000	0.510
2	45521	0.505
2	33878	0.500
1	30000	0.495

Price($)	Vol.	No.
0.540	22471	1
0.550	82295	3
0.600	25953	2
0.610	2000	1
0.000	0	0

Last trade - 15.41pm 09/07/2024 (20 minute delay)

FAR (ASX) Chart

An Ode to FAR....., page-92

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Patagonia looks to raise $2.15M for South American exploration and development

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

An Ode to FAR....., page-92

Top Stories

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Patagonia looks to raise $2.15M for South American exploration and development

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News